Evogene (EVGN) Competitors $1.30 +0.03 (+2.35%) Closing price 08/22/2025 03:50 PM EasternExtended Trading$1.31 +0.01 (+0.38%) As of 08/22/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVGN vs. CARM, SNES, SDST, TOMZ, BSLK, ENFY, GURE, NITO, CNEY, and HGASShould you be buying Evogene stock or one of its competitors? The main competitors of Evogene include Carisma Therapeutics (CARM), Senestech (SNES), Stardust Power (SDST), TOMI Environmental Solutions (TOMZ), Bolt Projects (BSLK), Enlightify (ENFY), Gulf Resources (GURE), N2OFF (NITO), CN Energy Group. (CNEY), and Global Gas (HGAS). Evogene vs. Its Competitors Carisma Therapeutics Senestech Stardust Power TOMI Environmental Solutions Bolt Projects Enlightify Gulf Resources N2OFF CN Energy Group. Global Gas Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Does the media refer more to CARM or EVGN? In the previous week, Evogene had 6 more articles in the media than Carisma Therapeutics. MarketBeat recorded 8 mentions for Evogene and 2 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.59 beat Carisma Therapeutics' score of 0.40 indicating that Evogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carisma Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evogene 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CARM or EVGN more profitable? Evogene has a net margin of -211.61% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -192.17% Evogene -211.61%-109.96%-38.47% Which has more risk & volatility, CARM or EVGN? Carisma Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Do institutionals and insiders hold more shares of CARM or EVGN? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, CARM or EVGN? Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.50-$60.48M-$1.56-0.15Evogene$8.51M0.82-$16.49M-$2.25-0.58 Do analysts recommend CARM or EVGN? Carisma Therapeutics presently has a consensus target price of $1.93, suggesting a potential upside of 715.68%. Evogene has a consensus target price of $3.50, suggesting a potential upside of 168.20%. Given Carisma Therapeutics' higher probable upside, equities research analysts clearly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71Evogene 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryCarisma Therapeutics and Evogene tied by winning 8 of the 16 factors compared between the two stocks. Get Evogene News Delivered to You Automatically Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVGN vs. The Competition Export to ExcelMetricEvogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7M$3.12B$5.83B$9.78BDividend YieldN/A2.23%4.40%4.05%P/E Ratio-0.5821.0031.3026.05Price / Sales0.82357.30455.25117.77Price / CashN/A44.5038.0259.36Price / Book0.568.129.536.60Net Income-$16.49M-$54.72M$3.26B$265.65M7 Day Performance-3.33%2.62%2.14%2.01%1 Month Performance-4.04%2.68%2.81%-0.33%1 Year Performance-66.37%10.93%30.70%19.04% Evogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVGNEvogene2.7039 of 5 stars$1.31+2.4%$3.50+168.2%-63.2%$7M$8.51M-0.58140CARMCarisma Therapeutics2.9892 of 5 stars$0.28-4.5%$1.93+590.0%-80.2%$12.20M$19.63M-0.1820News CoverageShort Interest ↓SNESSenestech2.1217 of 5 stars$4.80+2.8%$10.00+108.3%-5.2%$25.07M$2.09M-0.8830Short Interest ↑SDSTStardust Power2.9386 of 5 stars$0.41+0.9%$5.11+1,147.0%-95.9%$24.71MN/A-0.73N/ANews CoverageAnalyst RevisionTOMZTOMI Environmental Solutions2.1694 of 5 stars$0.91-1.1%$3.50+284.6%-12.1%$18.41M$7.74M-3.9620News CoverageAnalyst RevisionBSLKBolt ProjectsN/A$7.02-20.1%N/AN/A$18.12M$1.37M-2.7012News CoverageENFYEnlightifyN/A$1.02+1.0%N/AN/A$15.85M$95.85M-0.81424GUREGulf ResourcesN/A$0.72+5.3%N/A-36.7%$9.08M$13.92M-0.29420Short Interest ↓Gap DownNITON2OFF0.1452 of 5 stars$0.22+0.7%N/A-22.9%$7.27M$210K0.002CNEYCN Energy Group.0.5607 of 5 stars$2.23-1.8%N/A-69.8%$6.83M$50.96M0.00160Positive NewsShort Interest ↓Gap UpHGASGlobal GasN/A$0.11flatN/AN/A$911KN/A0.002 Related Companies and Tools Related Companies CARM Competitors SNES Competitors SDST Competitors TOMZ Competitors BSLK Competitors ENFY Competitors GURE Competitors NITO Competitors CNEY Competitors HGAS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVGN) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access